AUPH News and Press, Aurinia Pharmaceuticals Inc From 09/04/20

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105...

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Results Earnings Conference Call August 11, 2020, 04:30 PM ET Company Participants Glenn Schulman - SVP, Corporate Communications and IR Peter Greenleaf - CEO and Director Neil Solomons - Chief Medical Officer Max Colao - Chief Commer...

Aurinia Pharma (NASDAQ: AUPH ) : Q2 GAAP EPS of -$0.26 misses by $0.03 . Revenue of $0.03M in-line (flat Y/Y). Cash, cash equivalents and short term investments of ~$442.06M at July 31, 2020. Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, ...

- U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 - - Cash, cash equivalents and short term investments totaled approximately $442.06 million at July 31, 2020 - - Conference call and webcast to be hosted today at...

This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . Aurinia Pharmaceuticals ( AUPH ) is a Canadian drug company which has recently received expedited FDA review for i...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public ...

One day after moving higher in the market, Aurinia Pharmaceuticals (NASDAQ: AUPH) stock was deep in the loss column on Thursday. Optimism flowing from good news the previous day was erased by the Canadian biotech's announcement that it's floating a new, $200 million secondary stock issue con...

Gainers:  Milestone Pharmaceuticals (NASDAQ: MIST ) +105% . More news on: Milestone Pharmaceuticals Inc., RigNet, Inc., Brightcove Inc., Stocks on the move, , Read more ...